BioGaia’s results for the third quarter to exceed market expectations
(Figures in the brackets refer to the same period the previous year) During the third quarter of 2023, BioGaia's sales have been impacted by increased demand in EMEA, the Americas and APAC. The sales in EMEA were positively affected by quarterly variations for individual orders. For the third quarter, sales are preliminarily estimated at SEK 318 million (258), an increase of 23% (excluding foreign exchange effects, 17%). The operating profit for the third quarter is preliminarily estimated at SEK 120 million (94), an increase of 28%. BioGaia publishes the interim report for the